Compare CXM & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXM | EVO |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | CXM | EVO |
|---|---|---|
| Price | $5.48 | $2.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $8.28 | $7.00 |
| AVG Volume (30 Days) | ★ 3.7M | 26.4K |
| Earning Date | 06-03-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $857,200,000.00 | N/A |
| Revenue This Year | $2.52 | $1.37 |
| Revenue Next Year | $4.94 | $10.05 |
| P/E Ratio | $275.00 | ★ N/A |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $4.72 | $2.31 |
| 52 Week High | $9.40 | $4.42 |
| Indicator | CXM | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 48.47 |
| Support Level | $5.14 | $2.60 |
| Resistance Level | $5.60 | $2.93 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 82.21 | 54.52 |
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.